Carvedilol Dosage, prices, Side Effect, vendor, vitamins, Drug, delivery, Taj api

Sitemap | Contact Us

Welcome To Taj Pharmaceuticals Ltd API

© 2004 - 2019 Taj Pharmaceuticals Limited . All rights reserved

carvedilol top

India

Latin America/ Caribbean

Africa & Middle East

Asia

Russia

Europe

Carvedilol Manufacturers in India Suppliers Carvedilol Dossage Exporters Distributors Carvedilol api active pharmaceuticals ingredients Carvedilol manufacturers Side Effects bulk drugs raw material Dossage Carvedilol companies Side Effects Dossage Importers Carvedilol Dossage Carvedilol Exporters Carvedilol exporters Dossage FDA Dossage Carvedilol Dossage DMF Symptoms Dossage Generic Taj Pharmaceuticals Ltd.

active pharmaceutical ingredients suppliers pharmaceutical Carvedilol manufacturing pharmaceutical drugs pharmaceutical intermediates Carvedilol pharmaceutical chemicals pharmaceutical raw materials Carvedilol active pharmaceutical ingredients Carvedilol committee active pharmaceutical ingredients manufacturer Carvedilol Active Pharmaceutical Ingredients manufacturer Carvedilol exporter drug ingredients pharmaceuticals

Pharmaceuticals API Manufacturer Carvedilol, Carvedilol manufacturer India, Carvedilol product, Carvedilol products, Api preparation, Certificate of Analysis API manufacturer product, Carvedilol anti ulcer product, Certificate of Origin COA Carvedilol COS Carvedilol, pharmaceutical generic, pharmaceutical drug, medical, Carvedilol pharma healthcare, pharma patents, contract MSDS manufacturing Trader Carvedilol pharma, generic pharma, HCL pharma MSDS pharmaceutical products, pharmaceutical formulations, generic import API, Carvedilol expectorant Pharmaceutical GMP Method of analysis formulations manufacturer, Carvedilol DMF drug master file pharmaceutical Anti Cancer active ingredient exporter from India, pharma Carvedilol ingredients, api, HIV Carvedilol, tablets, capsules, syrup & protein Carvedilol powder, GMP of Plant api nutraceuticals, gynec products, ortho ingredients in India, oncology products, Carvedilol gastroenterology products, buy, sell orthopaedic product, who gmp, cGMP, US FDA, Carvedilol WHO, UKMHRA Approval

	PRODUCT LIST
	Home
	API >>>
	Pharmaceuticals API List
	Chemicals
	Manufacturing
	Product Development
	Product Search
	Agro Chemicals
	Custom Pharma Services
	Contact Us

carvedilol img.

HOME >> API >> API List1 >> Carvedilol >> Dosage

DOSAGE
Carvedilol CAS No [72956-09-3]

The starting dosage of carvedilol is 3.125 mg orally twice daily for two weeks. This dosage is the same regardless of the patient's age or weight. Because food slows the rate (but not the extent) of absorption, carvedilol should be taken with food to reduce the incidence of orthostatic hypotension. Patients should be observed in the physician's office for adverse reactions, especially dizziness, lightheadedness and hypotension, for one hour after the first dose and again after each dosage increase. Blood pressure should be measured with the patient standing. Patients should be instructed to weigh themselves every day and to contact their physician immediately if they experience a weight gain of 0.91 to 1.36 kg (2 to 3 lb) above their usual "dry" weight. If, after two weeks, the initial dosage of carvedilol has been well-tolerated, it should be doubled. The dosage should be doubled every two weeks to the maximum dosage or the highest tolerated dosage. The maximum recommended dosage for carvedilol is 25 mg twice daily in patients weighing less than 85 kg (187 lb) and 50 mg twice daily in patients weighing 85 kg (187 lb) or moreRecommendations for the administration and titration of carvedilol are summarized in Tables 3 and 4.It may also be necessary, based on clinical signs and symptoms, to adjust the dosages of the patient's other heart failure medications when carvedilol is introduced. When patients have signs and symptoms of excessive vasodilation, such as dizziness, lightheadedness or orthostatic hypotension, consideration should be given to decreasing diuretic, vasodilator or ACE inhibitor dosages. If these signs and symptoms persist, the dosage of carvedilol should be decreased. In patients with signs and symptoms of worsening heart failure, such as edema, weight gain or dyspnea, the dosage of diuretic therapy should be increased. If evidence of worsening heart failure persists, the dosage of carvedilol should be decreased. In patients with bradycardia or first-degree atrioventricular block, carvedilol should be titrated to maintain a heart rate greater than 55 beats per minute. Finally, patients should be advised not to stop taking carvedilol abruptly or without a physician's advice. When carvedilol therapy must be discontinued, the drug should be tapered slowly over seven to 14 days

Information Associated with Product:

DRUG DESCRIPTION

DOSAGE >>

SIDE EFFECTS

PRECAUTIONS

PATIENT INFORMATION

CONSUMER INFORMATION

PDF DOWNLOAD

WORD DOCUMENT


Product Enquiry	Product Quotation	Sample Request	Place Your Order

Taj Pharmaceuticals API Logo

Api Manufacturing At Taj

Acamprosate Calcium	Clomipramine Hcl	Alendronate Sodium	Clonazepam	Amitriptyline	Clopidogrel Bisulfate	Anastrozole	Danazol	Atomoxetine Hcl	Desloratadine	Balsalazide
Desmopressin Monoacetate	Bicalutamide	Divalproex Sodium	Budesonide	Dobutamine Hcl	Bupropion Hcl	Donepezil	Calcitonin	Dothiepin Hcl	Capecitabine	Entacapone
Carbamazepine	Eptifibatide	Carboplatin	Escitalopram HBr	Carisoprodol	Eszopiclone	Carvedilol	Finasteride	Cefuroxime Axetil	Flurbiprofen	Cisplatin
Fluticasone Propionate	Citalopram Hbr	Fluvoxamine Maleate	Fosphenytoin Sodium

Investor Relations Feedback Contact Worldwide Sitemap

© 2004 - 2019 Taj Pharmaceuticals Limited . All rights reserved
Note:-We are committed to helping you find the right answers to your questions and concerns. However, this web site is not intended to give investment advice, promote the use of Taj Pharmaceuticals Ltd products or provide information on which to base medical treatment. If you have questions regarding any Taj Pharmaceuticals Ltd product or are experiencing a medical emergency, please consult your health care provider.
Additionally, contact information on this web site cannot be used to report adverse drug events. If you are a physician, please follow the procedures required by your country's regulations. Please choose one of the given options to contact us and we will respond to your inquiry as quickly as possible.